[Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
However, in patients with epithelial ovarian cancer, the standard chemotherapy of paclitaxel/carboplatin (TC) therapy is very effective as the overall survival (OS) reached 70-80% in early stage (stage I/II ) patients, in advanced stage patients like stage III/IV the recurrence rate exceeds 80%and the 5-year-OS remains 55%at most. Longer survival remains so worse as well that the 10-year-OS fails to 5-7%. In order to push up the rate of longer survival, the strategies have been considered from the some points of view such as additional new anti-cancer agents, changing of drug delivery system (DDS) (i.e. intraperitoneal administration), additional radiotherapy or radioactive agents (in USA), the combination of molecular agents and specific classification in treatment using "Bio-markers (so-called tailor-made medicine)". Here we reviewed the up-coming treatments in maintenance fashion using anti-angiogenic agents or supposing effective and curable treatment by PARP inhibitors in the cohorts of epithelial ovarian cancers with BRCAness.